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Background: Atherosclerosis is an age-related disease. Adiponectin and C1q form a protein complex in human
blood, and that serum C1q and C1q-binding adiponectin (C1q-APN) concentrations can be measured. We
investigated circulating C1q and C1q-APN levels in Japanese men including elderly men.
Findings: The study subjects were 509 Japanese men including elderly men. Serum levels of total adiponectin
(Total-APN), high-molecular weight-adiponectin (HMW-APN), C1q-APN and C1q were measured by enzyme-linked
immunosorbent assay. Total-APN, HMW-APN and C1q-APN, but not C1q, correlated significantly and positively with
aging (r=0.26, r=0.24, r=0.17, p<0.01, respectively). The HMW-APN/Total-APN ratio correlated significantly and
positively with aging (r=0.14, p<0.01). The C1q-APN/Total-APN ratio and C1q-APN/HMW-APN ratio correlated
significantly and negatively with aging (r=−0.17, p<0.01, r=−0.12, p=0.01). C1q-APN/C1q correlated significantly and
positively with aging (r=0.09, p=0.03). Multiple regression analysis identified age and body mass index as significant
determinants of C1q-APN.
Conclusions: The present study demonstrates that serum HMW-APN, C1q-APN, and Total-APN, but not C1q,
correlated positively with aging. These preliminary results could form the basis for future research.
Trial registration: Clinical Trial Registration Number: UMIN000004318
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Atherosclerosis is an age-related disease [1]. Comple-
ment C1q activates canonical Wnt signaling and pro-
motes aging-related phenotypes [2]. Wnt signaling also
inhibits adipogenesis [3]. Adiponectin, which was identi-
fied by our group [4], has anti-atherosclerotic and anti-
inflammatory properties in experimental animals and
cells [5,6]. Adiponectin binds C1q in vitro, which in-
duces activation of the classical complement pathway
[7]. Our group reported recently that adiponectin and
C1q form a protein complex in human blood, and that
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reproduction in any medium, provided the orconcentrations can be measured using a new assay [8].
In the present study, we investigated circulating C1q and
C1q-APN levels in Japanese men including elderly men.Subjects and methods
Participants
The study subjects (Victor-J study: UMIN 000004318)
were 509 Japanese men; 500 male employees, who
underwent annual health checkup in 2010 at Hitachi
Ltd (Ibaraki, Japan) [average age; 55±9 years (30–74),
30′s; n=41, 40′s; n=101, 50′s; n=229, 60′s; n=98, 70′s;
n=31], and 9 residents of a geriatric health services facil-
ity at Minoh no Sato (Osaka, Japan) [average age; 84±11
years (71–100), 70′s; n=4, 80′s; n=2, 90′s; n=2, 100′s;
n=1]. The present study was approved by the human
ethics committees of Osaka University, Hitachi Healthal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Baseline characteristics
n (males) 509
Age, years 54±10 (30–100)
Body mass index (BMI), kg/m2 24.1±3.0 (14.8−36.5)
Hypertension, % (medication, %) 42.2 (23.8)
Systolic blood pressure (SBP), mmHg 123±12 (91–174)
Diastolic blood pressure (DBP), mmHg 78±8 (47–100)
Diabetes, % (medication, %) 33.6 (4.9)
Fasting blood glucose (FBG), mg/dL 109±18 (64–284)
Hemoglobin A1c (HbA1c), (NGSP), % 5.8±0.6 (4.5−10.2)
Estimated glomerular filtration rate (eGFR),
mL/min
69.4±12.8 (28.6−130.5)
Dyslipidemia, % (medication, %) 40.9 (12.4)
Total cholesterol (T-cho), mg/dL 204±33 (104–332)




History of myocardial infarction, angina, stroke,
heart failure, and renal failure, %
0.8/0.2/0.6/0.6/23.8
Smoking (none-/ex–/current-), % 26.2/48.0/25.8
Brinkman index 383±352 (0–2000)
Serum Total-APN, μg/mL 6.8±3.6 (1.1−34.8)
Serum HMW-APN, μg/mL 4.9±3.6 (0.2−32.3)
Serum C1q-APN, units/mL 67.8±19.8 (31.6−209.3)
Serum C1q, μg/mL 56.7±9.8 (17.3−84.2)
Serum HWM-APN/Total-APN ratio 0.7±0.2 (0.2−1.3)
Serum C1q-APN/Total-APN ratio 11.5±4.6 (2.6−44.3)
Serum C1q-APN/HMW-APN ratio 20.4±17.0 (2.8−225.3)
Serum C1q-APN/C1q ratio 1.2±0.5 (0.5−4.0)
Data are mean±SD (range), or number of subjects.
APN; adiponectin, HMW; high-molecular weight.
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ten informed consent was obtained from all subjects.
Anthropometric data and laboratory tests
Anthropometric variables [height, weight] were mea-
sured in the standing position and and body mass index
(BMI) was calculated [=weight (kg) / height (m)2]. Sys-
tolic and diastolic blood pressures (SBP, DBP) were
measured with a standard mercury sphygmomanometer
on the left or right arm in the standing position after at
least 5-minute rest. Venous blood samples were col-
lected in the morning after overnight fast for measure-
ments of serum creatinine, total cholesterol (T-cho),
triglyceride (TG), high-density lipoprotein-cholesterol
(HDL-C), glucose, and HbA1c (Japan Diabetes Society
[JDS]). The value of HbA1c (%) was estimated as the
National Glycohemoglobin Standardization Program
(NGSP) equivalent value (%), calculated by the formula
HbA1c (%) = HbA1c (JDS, %) + 0.4%. Low-density
lipoprotein-cholesterol (LDL-C) was calculated using
the Friedewald formula. Estimated GFR (eGFR) was cal-
culated using the simplified Modification of Diet in
Renal Disease equation modified by the appropriate co-
efficient for Japanese populations by gender, as described
previously [9]. Serum samples were obtained at base-
line from each participant and stored promptly at −20°C.
After thawing the samples, serum levels of total
adiponectin (Total-APN) and high-molecular weight-
adiponectin (HMW-APN) were measured by enzyme-
linked immunosorbent assay (ELISA) (Human adiponectin
ELISA kit, Human HMW-adiponectin ELISA kit, Otsuka
Pharmaceutical Co. Tokushima, Japan) [4,10]. Serum le-
vels of C1q-APN and C1q were measured by our
manufactured ELISA, as reported previously by our group
[8]. The intra- and inter-coefficients of variation (CV) for
C1q-APN ELISA are below 4.6% and 6.7%, respectively.
The intra- and inter-CV for C1q ELISA are below 4.6%
and 5.0%, respectively. Smoking status was collected
through a self-questionnaireis (non-, ex- or current-) and
Brinkman index (daily number of cigarettes × years).
Medical history was surveyed by using a self-administered
questionnaire including diabetes, dyslpidemia, hyperten-
sion, and past history of myocardial infarction, angina,
stroke [11]. Heart failure was defined as plasma brain
natriuretic peptide levels >100 pg/mL, and renal failure
was defined as plasma eGFR <60 mL/min.
Statistical analysis
Data are expressed as mean±SD. Relationships between
two continuous variables were analyzed using scatter plots
and Pearson’s correlation coefficient. The correlations be-
tween C1q-APN, C1q and clinical features, were first ana-
lyzed by univariate regression analysis and then by
multivariate regression analysis. In all cases, p values <0.05were considered statistically significant. All statistical
analyses were performed with The Statistical Package for
Social Sciences (version 11.0, SPSS Inc, Chicago, IL).
Results
Table 1 shows the characteristics of all male sub-
jects. Total-APN, HMW-APN and C1q-APN, but not
C1q, correlated significantly and positively with aging
(Figure 1A-D). The HMW-APN/Total-APN ratio corre-
lated significantly and positively with aging (Figure 1E).
The C1q-APN/Total-APN ratio and C1q-APN/HMW-
APN ratio correlated significantly and negatively with
aging (Figure 1F, G). C1q-APN/C1q correlated signifi-
cantly and positively with aging (Figure 1H).
Next, univariate regression analysis was used to evalu-
ate the relationship between C1q-APN, C1q and clinical
features (Table 2). C1q-APN correlated positively with
age and HDL-C, and negatively with BMI, and log TG.

























































































































































Figure 1 Correlations of circulating levels of Total-APN, HMW-APN, C1q-APN, C1q, HMW-APN/Total-APN, C1q-APN/Total-APN, C1q-APN/
HMW-APN, and C1q-APN/C1q with age. Abbreviations as in Table 1. Relationships between two continuous variables were analyzed by
Pearson’s correlation analysis. Solid lines: regression lines, Dotted lines: 95% confidence interval (CI) of predicted mean together with reference
lines indicating the baseline for each adiponectin parameter and C1q levels (0% change).
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determinants of C1q-APN. On the other hand, C1q cor-
related positively with BMI, SBP, DBP, T-cho, log TG
and negatively with HDL-C. Multiple regression analysis
of BMI, SBP, DBP, T-cho, log-TG and HDL-C identified
SBP and HDL-C as significant determinants of C1q.Discussion
This is the first report showing that serum HMW-APN
and C1q-APN as well as Total-APN, but not C1q, corre-
lated with aging, and that multiple regression analysisidentified age as well as BMI as significant determinants
of C1q-APN.
As one possible mechanism, three major factors are
involved in the control of circulating Total-APN levels;
gender, body weight and renal function [4,12,13]. The
present study found that advanced age is associated with
decreased body weight (r=−0.1612, p=0.0003) and re-
duced renal function (r=−0.2168, p<0.0001, data not
shown). These findings may provide an explanation for
the increased adiponectin levels in elderly men.
Another possible mechanism is dysregulated production
of adipocytokines in elderly subjects, especially hyper-
Table 2 Correlations between C1q-APN, C1q and clinical features in men
Log C1q-APN C1q
Univariate Multivariate Univariate Multivariate
r p p r p p
Age 0.1612 0.0002 0.0076 0.5661
BMI −0.2490 <0.0001 <0.0001 0.1549 0.0004 0.2761
SBP 0.7847 0.2074 <0.0001 0.0098




T-cho 0.1970 0.1095 0.0149 0.0910
Log-TG −01483 0.0009 0.1219 0.1949 <0.0001 0.2585
HDL-C 0.1095 0.0122 0.7865 −0.1845 <0.0001 0.0043
Brinkman index 0.2472 0.9811
adjusted r2 0.071 0.089
Data of C1q-APN and TG levels showed skewed distribution and were log-transformed before analysis. Significant level was set at p<0.05 (bold typeface). Multiple
regression analysis was conducted to identify those parameters that significantly contributed to C1q-APN or C1q. Parameters with p<0.05 were subsequently
entered into the regression analysis as independent variables (bold typeface). Abbreviations as in Table 1.
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process [14]. The data suggests that age-related lipoa-
trophy may be the major factor for adipose tissue dysfunc-
tion in advanced age. Transgenic expression of human
adiponectin blocked excessive fat accumulation and re-
duced morbidity and mortality rates in mice fed high-
calorie diet, and prolonged the lifespan of normal mice, by
inhibiting AKT signaling and chronic inflammation [15].
Based on our recent studies [8,16,17], low Total-APN and
high C1q-APN/Total-APN correlated with coronary artery
disease, suggesting that adiponectin may protect against
the development of atherosclerosis through the activation
of the complement system and that it can modulate the
self-defense system through its binding with C1q in the
peripheral circulation. The present study demonstrates
that high Total-APN and low C1q-APN/Total-APN ratio
correlated positively, but not strongly, with aging (Figure 1).
Recent study suggests that centenarians possess a different
adiponectin isoform pattern [18]. Taken together, high
Total-APN levels and low C1q-APN/Total-APN ratio
seems to inhibit aging-related phenotypes including athero-
sclerosis, and, at least partly, may live longer than others.
Further longitudinal studies of larger populations of elderly
subjects are required.Conclusion
The present study demonstrated that serum HMW-APN,
C1q-APN, and Total-APN, but not C1q, correlated posi-
tively with aging.Study limitations
Certain limitations of this study must be considered. First,
this is a cross-sectional study, making it difficult to estab-
lish a cause-effect relationship. Further prospective studies
should be conducted to analyze this relationship. Second,
all patients in this study were Japanese men and any differ-
ences from other ethnic groups are unknown. The results
may not be applicable to females or non-Japanese popula-
tions. The other preliminary study analyzed the correl-
ation of circulating C1q-APN concentrations with aging in
Japanese females (n=144, average age (range), 45±10 years
(23–64), 20′s; n=10, 30′s; n=36, 40′s; n=46, 50′s; n=46,
60′s; n=6). Total-APN, but not C1q-APN, correlated posi-
tively with age (r=0.20, p=0.013). However, Adamczak
et al. reported that plasma adiponectin concentration in
females did not change significantly with age [19]. In our
preliminary study, the number of over 60′s elderly sub-
jects may be still small, and further investigations are re-
quired. Third, the current study did not include the effects
of physical activity, alcohol intake, socio-economic status,
marital status, dietary habit and use of pharmacothe-
rapy. Fourth, medical history surveyed by using a self-
administered questionnaire remains some ambiguities.
Finally, in Japan, employees shall be liable to undergo an-
nual health checkup until the age of retirement (65 years).
On the other hand, the elderly aged 65 or over have no
obligation to undergo annual health checkup in medical
insurance system. In Japan, apparently healthy elders were
residents of a geriatric health services facility who have
few serious diseases, but not hospitalized patients. We
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participate in this study. The number of over 70′s elderly
subjects may be still small. Therefore the present study
has a selection bias. Further investigations might be re-
quired to confirm the present results.
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